Joshua Fitch is an editor for Contemporary Pediatrics.
Nirsevimab recommended by FDA Advisory Committee to prevent RSV in infants
June 9th 2023In unanimous fashion, the FDA AMDAC voted 21 to 0 that nirsevimab has a favorable benefit risk profile for the prevention of RSV lower respiratory tract disease (LRTD) in newborns and infants during their first RSV season.
Medicaid-enrolled children not receiving mental health services after firearm injuries
June 8th 2023Investigators state public health strategies should prioritize early detection of mental health needs and equitable access to it, as some Medicaid-enrolled children are not receiving mental health services following a firearm injury.
FDA warns of drug compounding amid shortages of drugs containing semaglutide
June 7th 2023Semaglutide (Wegovy; Novo Nordisk) for obesity in adolescents, along with 2 other approved products containing semaglutide, are currently on the FDA’s drug shortages list, prompting the agency to warn patients and providers about drug compounding.
Early risk factors associated with behavioral dysregulation trajectories
June 2nd 2023Risk detection practices and targeted interventions promoting adaptive developmental trajectories for at-risk children can be successful by identifying the earliest antecedents of persisting emotional and behavioral dysregulation.
Getting children's mental health on track
May 31st 2023In this Contemporary Pediatrics® interview, Benjamin Maxwell, MD, chief of child and adolescent psychiatry, Rady Children’s Hospital, San Diego, California, details the rise in pediatric mental health concerns, emergency department visits, and the potentially concerning aspects of social media among youth.
How AI can help detect and monitor coughing in infants and young children
May 31st 2023Devan Jaganath, MD, MPH, pediatric infectious disease physician, University of California San Francisco Benioff Children's Hospitals, explains how Hyfe AI and other artificial intelligence algorithms can detect and monitor coughing, potentially playing a role in treating RSV patients.
Here’s what parents think of pre-owned child health and safety equipment
May 25th 2023Over 50% of parents said they have used pre-owned child health and safety equipment. Whether it comes from family or a stranger, from cribs to car seats, all equipment should be inspected and researched before allowing a child to use it according to a C.S. Mott Children’s Hospital National Poll on Children’s Health.
FDA clears algorithm-based automated insulin dosing system for T1D patients 6 years and up
May 25th 2023The Beta Bionics iLet ACE Pump and the iLet Dosing Decision software, matched with a compatible FDA-cleared integrated continuous glucose monitor, use an algorithm to determine and command insulin delivery to users.
Surgeon General issues advisory regarding effects social media has on youths’ mental health
May 24th 2023Up to 95% of youth aged 13 to 17 years reported using a social media platform and more than a third said they use social media, “almost constantly,” according to a new advisory from the Surgeon General.
FDA approves adalimumab-adbm autoinjector pen for JIA, Crohn’s disease
May 22nd 2023Patients using adalimumab-adbm for chronic inflammatory disease treatment such as juvenile idiopathic arthritis (JIA), Crohn’s disease, and others, will have an autoinjector option beginning July 1, 2023, according to Boehringer Ingelheim.
How FDA-approved B-VEC will help children with dystrophic epidermolysis bullosa
May 20th 2023Following the FDA approval of beremagene geperpavec (B-VEC) (Vyjuvek; Krystal Biotech) to treat dystrophic epidermolysis bullosa (DEB) patients aged 6 months and older, Bernard A. Cohen, MD, discusses its safety and efficacy and how it can change the treatment landscape for DEB.
FDA approves B-VEC to treat dystrophic epidermolysis bullosa patients 6 months and older
May 19th 2023The FDA has approved Krystal Biotech's beremagene geperpavec (B-VEC) (Vyjuvek; Krystal Biotech) to treat the wounds of dystrophic epidermolysis bullosa (DEB) patients aged 6 months and older. B-VEC is the first FDA-approved gene therapy treatment for DEB, according to the agency. In this Contemporary Pediatrics interview, Raj Chovatiya, MD, PhD, breaks down this much-anticipated FDA approval.
Pfizer's infant RSV vaccine receives FDA Advisory Committee's support
May 19th 2023The FDA Advisory Committee recently voted in support of approval for Pfizer's maternal immunization vaccine to help prevent RSV in infants. In this Contemporary Pediatrics® interview, Tina Tan, MD, FAAP, FIDSA, FPIDS, pediatric infectious diseases attending, Ann & Robert H. Lurie Children's Hospital, Chicago, explains what this means for this patient population ahead of an expected FDA decision in August, 2023.
Early screening can play a critical role in pediatric mental health
May 17th 2023Thomas R. Young, MD, discusses how important early screening is in children and adolescents with regard to mental health. He believes a reduction in stigma associated with mental health is occurring and that primary care professionals are encouraging youth to discuss what might be bothering them.
Tapinarof cream 1% demonstrates positive topline results for treating pediatric AD
May 16th 2023The once-daily topical cream for the treatment of atopic dermatitis (AD) has demonstrated positive topline results in 2 phase 3 studies in adults and children aged 2 years and up. According to Dermavant, a supplemental new drug application (sNDA) filed with the FDA is anticipated in Q1 of 2024.
Glucose levels are in target range at higher percentage with hybrid closed-loop system
May 16th 2023A hybrid closed-loop system can deliver glucose levels in the target range at a higher percentage of time among children aged 2 years to younger than 6 years compared to standard-care, according to a study in the New England Journal of Medicine.
What questions do pediatricians need to be prepared for as the federal COVID-19 PHE expires?
May 11th 2023Contemporary Pediatrics® Editorial Advisory Board member Andrew Schuman, MD, clinical assistant professor of pediatrics, Geisel School of Medicine, Dartmouth, shares some questions pediatricians can expect from parents as the federal COVID-19 public health emergency (PHE) expires.
Tina Tan, MD, discusses cost burden associated with the COVID-19 public health emergency expiration
May 11th 2023Tina Tan, MD, FAAP, FIDSA, FPIDS, editor-in-chief, Contemporary Pediatrics®, discusses how the cost burden of the federal COVID-19 public health emergency (PHE) expiration on May 11, 2023, can impact testing and vaccination rates among children.